Skip to main content

Advertisement

SpringerLink
Log in

A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice

  • Published:
Translational Stroke Research Aims and scope Submit manuscript

Abstract

Thrombolysis remains a mainstay in the treatment of ischemic stroke. While not usually considered in the spectrum of clot lysis, experimental data show that inhibition of the platelet glycoprotein (GP) IIb/IIIa receptor can reduce as well as reverse thrombus formation and improve microvascular flow in stroke models. However, a recent clinical trial of GP IIb/IIIa inhibition in stroke did not demonstrate clinical benefit and was associated with increased hemorrhage. Based on an understanding of the relationship between GP IIb/IIIa receptor inhibition, efficacy and hemorrhage, we hypothesized that a lower dose of abciximab would achieve a favorable range of platelet inhibition and potentially good clinical outcomes. Forty-four patients with suspected large vessel occlusion, who were not eligible for rt-PA were offered treatment with approximately 30% lower total dose of intravenous abciximab if within 6 h for anterior circulation or 24 h for posterior circulation stroke (later modified to 12 h). Concomitant anticoagulation, usually with unfractionated heparin was employed. The extent of platelet inhibition was measured in 21 patients. Hemorrhage rate and 90-day functional outcomes and mortality were obtained. A matching algorithm involving finding the nearest neighbor from individual subjects in the control arm of the NINDS rt-PA database was used to compare outcomes at similar baseline characteristics and gender. Mean platelet inhibition was 92.1 ± 6.7% vs inhibition reported with percutaneous coronary intervention (PCI) of 96 ± 10; p = 0.08. Successful matching to NINDS controls was accomplished: after outlier elimination, median and mean NIHSS of the abciximab subjects compared to NINDS controls was 16.5 vs 15.5 (p = 0.92) and 16.3 vs 16.0 (p = 0.86). Mean age was 67.2 vs 67.1 (p = 0.97). Mean glucose was 141 vs 142 (p = 0.92). There was one symptomatic hemorrhage; minor hemorrhages occurred in 9%. The percent of patients who achieved an mRS 0–2 or died in the treated vs matched NINDS control patients was 63 vs 38 (p = .02) and 23 vs 23 (p = 1.0). Our pilot results indicated that a lower dose of abciximab results in platelet inhibition similar to that achieved in the coronary vascular bed during PCI. Comparison to matched historical controls suggests that this lower dose in combination therapy may be safe and effective therapy for thrombotic stroke and a randomized trial is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lo E, Broderick JP, Moskowitz MA. tPA and proteolysis in the neurovascular unit. Stroke. 2004;35:354–6.

    Article  PubMed  Google Scholar 

  2. Mandava P, Kent TA. Intra-arterial therapies for acute ischemic stroke. Neurology. 2007;68:2132–9.

    Article  PubMed  Google Scholar 

  3. Mandava P, Suarez JI, Kent TA. Intravenous rt-PA versus endovascular therapy for acute ischemic stroke. Curr Atheroscl Rep. 2008;40:1803–10.

    Google Scholar 

  4. Mandava P, Kent TA. A method to determine stroke trial success using multidimensional pooled control functions. Stroke. 2009;40:1803–10.

    Article  PubMed  Google Scholar 

  5. Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol. 2003;42:1178–85.

    Article  CAS  PubMed  Google Scholar 

  6. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percuataneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569–78.

    Article  Google Scholar 

  7. Adams HP, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al. Emergency administration of Abciximab for treatment of patients with acute ischemic stroke: results of an International Phase III Trial: Abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke. 2008;39:87–99.

    Article  CAS  PubMed  Google Scholar 

  8. Mandava P, Thiagarajan P, Kent TA. Glycoprotein IIb/IIIa antagonists in acute Ischaemic stroke. Current status and future directions. Drugs. 2008;68:1019–28.

    Article  CAS  PubMed  Google Scholar 

  9. Choudhri TF, Hoh BL, Zerwes H-G, Prestigiacomo CJ, Kim SC, Connolly Jr ES, et al. Reduced microvascular Thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 1998;102:1301–10.

    Article  CAS  PubMed  Google Scholar 

  10. Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, et al. Integrin αIIbβ3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke. 2000;31:1402–10.

    CAS  PubMed  Google Scholar 

  11. Ding G, Jiang Q, Zhang L, Zhang ZG, Li L, Knight RA, et al. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIB/IIIa inhibitor. JCBF. 2005;25:87–97.

    CAS  Google Scholar 

  12. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation. 1989;80:1766–74.

    CAS  PubMed  Google Scholar 

  13. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115:2323–30.

    Article  CAS  PubMed  Google Scholar 

  14. Samra SK, Harrison RL, Bee DE, Valero V. A study of aspirin induced changes in bleeding time, platelet aggregation, and Sonoclot coagulation analysis in humans. Ann Clin Lab Sci. 1991;21:315–27.

    CAS  PubMed  Google Scholar 

  15. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. 2005;36:880–90.

    Article  Google Scholar 

  16. Theroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefit. Am Heart J. 1997;134:S62–70.

    CAS  PubMed  Google Scholar 

  17. The Epic Investigators. Use of monoclonal antibody directed against the platelet glycoprotein iib/iiia receptor in high risk coronary angioplasty. N Eng J Med. 1994;330:956–61.

    Article  Google Scholar 

  18. The Impact II investigators. Randomized placebo controlled trial of eptifibatide on complications of percutaneous coronary intervention:IMPACT-II. Integrilin to minimize platelet aggregation and coronary thrombosis-II. Lancet. 1997;349:1422–8.

    Article  Google Scholar 

  19. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7e3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation. 1997;95:1755–9.

    CAS  PubMed  Google Scholar 

  20. Mandava P, Kalkonde YV, Rochat R, Kent TA. A matching algorithm to address imbalances in study populations. Application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator Acute Stroke Trial. Stroke. 2010;41:765–70.

    Article  PubMed  Google Scholar 

  21. Cheung RT, Ho DS. Fatal hemorrhagic transformation of acute cerebral infarction after the use of abciximab. Stroke. 2000;31:2526–7.

    CAS  PubMed  Google Scholar 

  22. Lee KY, Heo JH, Lee SI, Yoon PH. Rescue treatment with abciximab in acute ischemic stroke. Neurology. 2001;56:1585–7.

    CAS  PubMed  Google Scholar 

  23. Mandava P, Lick SD, Rahman MA, Langsjoen H, Reddy KV, Nelson J, et al. Initial safety experience of abciximab and heparin for acute ischemic stroke. Cerebrovasc Dis. 2005;19:276–8.

    Article  PubMed  Google Scholar 

  24. Mandava P, Kent TA. Reversal of dense signs predicts recovery in acute ischemic stroke. Stroke. 2005;36:2490–2.

    Article  PubMed  Google Scholar 

  25. Steinhubl SR, Kottke-Marchant K, Moliterno DJ. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation. 1999;100:1977–82.

    CAS  PubMed  Google Scholar 

  26. Steinhubl SR, Talley D, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) Multicenter Study. Circulation. 2001;103:2572–8.

    CAS  PubMed  Google Scholar 

  27. Steinhubl SR. Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonist. Coron Artery Dis. 2003;14:381–6.

    Article  PubMed  Google Scholar 

  28. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.

    Article  Google Scholar 

  29. Bergstralh EJ, Kosanke JL. Computerized matching of cases to controls. Technical report 56. Available at http://mayoresearch.mayo.edu/mayo/research/biostat/upload/56.pdf. Accessed 2 April 2010.

  30. NIST/SEMATECH e-Handbook of Statistical Methods. Available at www.itl.nist.gov/div898/handbook/ Chapters 1&7. Accessed 2 April 2010.

  31. Dachs RJ, Burton H, Joslin J. A user's guide to the NINDS rt-PA stroke trial database. PLoS Med. 2008;5:e113.

    Article  PubMed  Google Scholar 

  32. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–25.

    Article  CAS  PubMed  Google Scholar 

  33. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245–51.

    Article  CAS  PubMed  Google Scholar 

  34. Ali M, Bath PM, Curram J, Davis SM, Diener HC, Donnan GA, et al. The virtual international stroke trials archive. Stroke. 2007;38:1905–10.

    Article  PubMed  Google Scholar 

  35. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in responses to recombinant tissue plasminogen activator in acute ischemic stroke. A pooled analysis of randomized clinical trials. Stroke. 2005;36:62–5.

    Article  CAS  PubMed  Google Scholar 

  36. Uchino K, Billheimer D, Cramer SC. Entry criteria and baseline characteristics predict outcome in acute stroke trials. Stroke. 2001;32:909–16.

    CAS  PubMed  Google Scholar 

  37. Weimar C, König IR, Kraywinkel K, Ziegler A, Diener HC, German Stroke Study Collaboration. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke. 2004;35:158–62.

    Article  CAS  PubMed  Google Scholar 

  38. Bruno A, Williams LS, Kent TA. How important is hyperglycemia during acute brain infarction? Neurologist. 2004;10:195–200.

    Article  PubMed  Google Scholar 

  39. Matlab. The language of technical computing. The Mathworks Inc. Boston, MA. Pp11.18-11.37.

  40. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Intervent. 2009;2:222–9.

    Article  Google Scholar 

  41. Wong PC, Crain EJ, Watson CA, Jiang X, Hua J, Bostwick JS, et al. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits. J Cardiovasc Pharmacol. 2007;49:316–24.

    Article  CAS  PubMed  Google Scholar 

  42. Ingall AH, Dixon JD, Bailey A, Coombs ME, Cox D, McInally JI, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem. 1999;42:213–20.

    Article  CAS  PubMed  Google Scholar 

  43. Lampl Y, Jivin JA, Fisher M, Lew R, Welin L, Dahlof B, et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke. 2007;38:1843–9.

    Article  PubMed  Google Scholar 

  44. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke. The CLEAR Stroke Trial. Stroke. 2008;39:3268–76.

    Article  CAS  PubMed  Google Scholar 

  45. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003–11.

    Article  CAS  PubMed  Google Scholar 

  46. Hacke W, Kaste M, Bluhmki E, Brozman M, Davolos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.

    Article  CAS  PubMed  Google Scholar 

  47. Grotta JC. National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. The NINDS Stroke Study Group response. J Stroke Cerebrovasc Dis. 2002;11:121–4.

    Article  PubMed  Google Scholar 

  48. Ingall TJ, O’Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, et al. Findings from the reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial. Stroke. 2004;35:2418–24.

    Article  CAS  PubMed  Google Scholar 

  49. Ribo M, Molina C, Montaner J, Rubiera M, Delgado-Mederos R, Arenillas JF, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke. 2005;36:1705–9.

    Article  CAS  PubMed  Google Scholar 

  50. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. JCBF. 2007;27:435–51.

    CAS  Google Scholar 

  51. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke. 2000;31:601–9.

    Google Scholar 

  52. Phillipps J, Thomalla G, Glahn J, Schwarze M, Röther J. Treatment of progressive stroke with tirofiban-experience in 35 patients. Cerebrovasc Dis. 2009;28:435–8.

    Article  Google Scholar 

  53. Martin-Schild S, Shaltoni H, Abraham AT, Barreto AD, Hallevi H, Gonzales NR, et al. Safety of eptifibatide for subcortical stroke progression. Cerebrovasc Dis. 2009;28:595–600.

    Article  CAS  PubMed  Google Scholar 

  54. Torgano G, Zecca B, Monzani V, Maestroni A, Rossi P, Cazzaniga M, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. Cerebrovasc Dis. 2010;29:275–81.

    Article  CAS  PubMed  Google Scholar 

  55. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112:3011–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This research was supported in part by the South Central VA Health Care Network Research Grants Program.

Author information

Authors and Affiliations

  1. Michael E. DeBakey VA Medical Center Stroke Program and Department of Neurology, Baylor College of Medicine, 2002 Holcombe Blvd (127), Houston, TX, 77030, USA

    Pitchaiah Mandava, William Dalmeida, Jane A. Anderson, Roderic H. Fabian & Thomas A. Kent

  2. Department of Medicine/Division of Thrombosis Research, Baylor College of Medicine, 2002 Holcombe Blvd (127), Houston, TX, 77030, USA

    Perumal Thiagarajan

  3. Interventional Neuroradiology, Michael E DeBakey VA Medical Center, 2002 Holcombe Blvd (127), Houston, TX, 77030, USA

    Raymond U. Weir

Authors
  1. Pitchaiah Mandava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William Dalmeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jane A. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Perumal Thiagarajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roderic H. Fabian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raymond U. Weir
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas A. Kent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pitchaiah Mandava.

Additional information

Disclosures

Drs. Mandava and Kent hold the copyright for PPREDICTS© and a patent application has been submitted on their behalf for PPREDICTS©.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mandava, P., Dalmeida, W., Anderson, J.A. et al. A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice. Transl. Stroke Res. 1, 170–177 (2010). https://doi.org/10.1007/s12975-010-0026-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12975-010-0026-4

Keywords

Search

Navigation